keyword
MENU ▼
Read by QxMD icon Read
search

Hiv treatment side effects

keyword
https://www.readbyqxmd.com/read/28086877/treating-the-invisible-gaps-and-opportunities-for-enhanced-tb-control-along-the-thailand-myanmar-border
#1
Naomi Tschirhart, Sein Sein Thi, Lei Lei Swe, Francois Nosten, Angel M Foster
BACKGROUND: In Thailand's northwestern Tak province, contextual conditions along the border with Myanmar pose difficulties for TB control among migrant populations. Incomplete surveillance data, migrant patient mobility, and loss to follow-up make it difficult to estimate the TB burden and implement effective TB control measures. This multi-methods study examined tuberculosis, tuberculosis and human immunodeficiency virus co-infection, and multidrug-resistant tuberculosis treatment accessibility for migrants and refugees in Tak province, health system response, and public health surveillance...
January 13, 2017: BMC Health Services Research
https://www.readbyqxmd.com/read/28063460/managing-two-decades-of-visceral-leishmaniasis-and-hiv-co-infection-a-case-report-that-illustrates-the-urgent-research-needs-in-the-field
#2
Melissa L Kelly, Angie N Pinto, Dan Suan, Debbie Marriott, David A Cooper, Sarah L Pett
Visceral leishmaniasis and HIV co-infection presents diagnostic, monitoring and treatment challenges. This is a report of a co-infected patient who developed multiple complications and treatment side-effects, including renal and liver failure, pancytopenia with recurrent sepsis, along with anal cancer, depression and poor quality-of-life spanning over two decades. Urgent research specific to this cohort is needed.
January 9, 2017: Sexual Health
https://www.readbyqxmd.com/read/28051797/%C3%A2-sofosbuvir-and-daclatasvir-in-mono-and-hiv-coinfected-patients-with-recurrent-hepatitis-c-after-liver-transplant
#3
Lluís Castells, Jordi Llaneras, Isabel Campos-Varela, Itxarone Bilbao, Manel Crespo, Oscar Len, Francisco Rodríguez-Frías, Ramon Charco, Teresa Salcedo, Juan Ignacio Esteban, Rafael Esteban-Mur
:  Background and aims. Pegylated interferon (Peg-INF) and ribavirin (RBV) based therapy is suboptimal and poorly tolerated. We evaluated the safety, tolerability and efficacy of a 24-week course of sofosbuvir plus daclatasvir without ribavirin for the treatment of hepatitis C virus (HCV) recurrence after liver transplantation (LT) in both HCV-monoinfected and human immunodeficiency virus (HIV)-HCV coinfected patients. MATERIAL AND METHODS: We retrospectively evaluated 22 consecutive adult LT recipients (16 monoinfected and 6 coinfected with HIV) who received a 24-week course of sofosbuvir plus daclatasvir treatment under an international compassionate access program...
January 2017: Annals of Hepatology
https://www.readbyqxmd.com/read/28028587/safety-of-zidovudine-lamivudine-scored-tablets-in-children-with-hiv-infection-in-europe-and-thailand
#4
Ali Judd
BACKGROUND: Zidovudine (ZDV) has been associated with risk of haematological toxicity. Safety data from clinical trials is generally limited to 48 weeks. We assessed the short- and mid-term toxicity of ZDV/lamivudine (3TC) fixed-dose combination scored tablets in HIV-infected children followed in the European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) network. METHODS: Fourteen cohorts provided data on patients <18 years of age taking ZDV/3TC scored tablets between 2008 and 2012...
December 27, 2016: European Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28011960/visceral-leishmaniasis-in-immunocompromised-diagnostic-and-therapeutic-approach-and-evaluation-of-the-recently-released-idsa-guidelines
#5
Pasquale Pagliano, Tiziana Ascione, Giusy Di Flumeri, Giovanni Boccia, Francesco De Caro
Visceral Leishmaniasis (VL) is a chronic infectious disease endemic in tropical and sub-tropical areas including the Mediterranean basin, caused by a group of protozoan parasites of the genus Leishmania and transmitted by phlebotomine sandflies. Typically, VL is classified as a zoonotic infection when Leishmania infantum is the causative agent and as an anthroponotic one when L. donovani is the causative agent. Immunocompromised patients, in particular HIV positive, are considered at risk of VL. They may present atypical signs and poor response to the treatment due to a compromission of T-helper and regulatory cells activity...
1, 2016: Le Infezioni in Medicina
https://www.readbyqxmd.com/read/28008980/antiretroviral-treatment-with-efavirenz-disrupts-the-blood-brain-barrier-integrity-and-increases-stroke-severity
#6
Luc Bertrand, Levi Dygert, Michal Toborek
The introduction of antiretroviral drugs (ARVd) changed the prognosis of HIV infection from a deadly disease to a chronic disease. However, even with undetectable viral loads, patients still develop a wide range of pathologies, including cerebrovascular complications and stroke. It is hypothesized that toxic side effects of ARVd may contribute to these effects. To address this notion, we evaluated the impact of several non-nucleoside reverse transcriptase inhibitors (NNRTI; Efavirenz, Etravirine, Rilpivirine and Nevirapine) on the integrity of the blood-brain barrier, and their impact on severity of stroke...
December 23, 2016: Scientific Reports
https://www.readbyqxmd.com/read/28006001/detectable-viral-load-in-late-pregnancy-among-women-in-the-rwanda-option-b-pmtct-program-enrollment-results-from-the-kabeho-study
#7
Michelle M Gill, Heather J Hoffman, Emily A Bobrow, Placidie Mugwaneza, Dieudonne Ndatimana, Gilles F Ndayisaba, Cyprien Baribwira, Laura Guay, Anita Asiimwe
There are limited viral load (VL) data available from programs implementing "Option B+," lifelong antiretroviral treatment (ART) to all HIV-positive pregnant and postpartum women, in resource-limited settings. Extent of viral suppression from a prevention of mother-to-child transmission of HIV program in Rwanda was assessed among women enrolled in the Kigali Antiretroviral and Breastfeeding Assessment for the Elimination of HIV (Kabeho) Study. ARV drug resistance testing was conducted on women with VL>2000 copies/ml...
2016: PloS One
https://www.readbyqxmd.com/read/27993121/trimethyl-chitosan-improves-anti-hiv-effects-of-atripla-as-a-new-nano-formulated-drug
#8
Sepideh Shohani, Asghar Abdoli, Behzad Khansarinejad, Mehdi Shafiee Ardestani, Mohammad Salimi-Asl, Maryam Ghanbari, Mehrdad Sadeghi Haj, Rezvan Zabihollahi, Mahdieh Mondanizadeh
Background; highly active antiretroviral therapy (HAART) has been commonly used for HIV treatment. Its main drawbacks like drug resistance and side effects raised researcher's interest to find new approaches for its treatment. Trimethyl chitosan is one of the drug carriers which was introduced recently. Materials and Methods; the conjugated atripla-trimethyl chitosan was designed and characterized by zetasizer, AFM and FTIR techniques. The drug conjugation with trimethyl chitosan and cellular uptake of nano-conjugate were determined by spectrophotometry...
December 16, 2016: Current HIV Research
https://www.readbyqxmd.com/read/27989126/iron-chelation-nanoparticles-with-delayed-saturation-as-an-effective-therapy-for-parkinson-disease
#9
Nan Wang, Xin Jin, Dongbo Guo, Gangsheng Tong, Xinyuan Zhu
Iron accumulation in substantia nigra pars compacta (SNpc) has been proved to be a prominent pathophysiological feature of Parkinson's diseases (PD), which can induce the death of dopaminergic (DA) neurons, up-regulation of reactive oxygen species (ROS), and further loss of motor control. In recent years, iron chelation therapy has been demonstrated to be an effective treatment for PD, which has shown significant improvements in clinical trials. However, the current iron chelators are suboptimal due to their short circulation time, side effects, and lack of proper protection from chelation with ions in blood circulation...
December 29, 2016: Biomacromolecules
https://www.readbyqxmd.com/read/27959728/effect-of-hiv-antibody-vrc01-on-viral-rebound-after-treatment-interruption
#10
MULTICENTER STUDY
Katharine J Bar, Michael C Sneller, Linda J Harrison, J Shawn Justement, Edgar T Overton, Mary E Petrone, D Brenda Salantes, Catherine A Seamon, Benjamin Scheinfeld, Richard W Kwan, Gerald H Learn, Michael A Proschan, Edward F Kreider, Jana Blazkova, Mark Bardsley, Eric W Refsland, Michael Messer, Katherine E Clarridge, Nancy B Tustin, Patrick J Madden, KaSaundra Oden, Sijy J O'Dell, Bernadette Jarocki, Andrea R Shiakolas, Randall L Tressler, Nicole A Doria-Rose, Robert T Bailer, Julie E Ledgerwood, Edmund V Capparelli, Rebecca M Lynch, Barney S Graham, Susan Moir, Richard A Koup, John R Mascola, James A Hoxie, Anthony S Fauci, Pablo Tebas, Tae-Wook Chun
Background The discovery of potent and broadly neutralizing antibodies (bNAbs) against human immunodeficiency virus (HIV) has made passive immunization a potential strategy for the prevention and treatment of HIV infection. We sought to determine whether passive administration of VRC01, a bNAb targeting the HIV CD4-binding site, can safely prevent or delay plasma viral rebound after the discontinuation of antiretroviral therapy (ART). Methods We conducted two open-label trials (AIDS Clinical Trials Group [ACTG] A5340 and National Institutes of Health [NIH] 15-I-0140) of the safety, side-effect profile, pharmacokinetic properties, and antiviral activity of VRC01 in persons with HIV infection who were undergoing interruption of ART...
November 24, 2016: New England Journal of Medicine
https://www.readbyqxmd.com/read/27937092/cetuximab-plus-chemoradiotherapy-for-hiv-associated-anal-carcinoma-a-phase-ii-aids-malignancy-consortium-trial
#11
Joseph A Sparano, Jeannette Y Lee, Joel Palefsky, David H Henry, William Wachsman, Lakshmi Rajdev, David Aboulafia, Lee Ratner, Thomas J Fitzgerald, Lisa Kachnic, Ronald Mitsuyasu
Purpose Squamous cell carcinoma of the anal canal (SCCAC) is characterized by high locoregional failure (LRF) rates after definitive chemoradiation (CRT), associated with anogenital human papilloma virus, and often appears in HIV infection. Because cetuximab enhances the effect of radiation therapy in human papilloma virus-associated oropharyngeal SCC, we hypothesized that adding cetuximab to CRT would reduce LRF in SCCAC. Methods Forty-five patients with stage I to III SCCAC and HIV infection received CRT: 45 to 54 Gy radiation therapy to the primary tumor and regional lymph nodes plus eight once-weekly doses of concurrent cetuximab and two cycles of cisplatin and fluorouracil...
December 12, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27930607/counseling-framework-for-hiv-serodiscordant-couples-on-the-integrated-use-of-antiretroviral-therapy-and-pre-exposure-prophylaxis-for-hiv-prevention
#12
Jennifer F Morton, Connie Celum, John Njoroge, Agnes Nakyanzi, Imeldah Wakhungu, Edna Tindimwebwa, Snaidah Ongachi, Eric Sedah, Emmanuel Okwero, Kenneth Ngure, Josephine Odoyo, Nulu Bulya, Jessica E Haberer, Jared M Baeten, Renee Heffron
BACKGROUND: For HIV-serodiscordant couples, integrated delivery of antiretroviral therapy (ART) for HIV-positive partners and time-limited pre-exposure prophylaxis (PrEP) for negative partners virtually eliminates HIV transmission. Standardized messaging, sensitive to the barriers and motivators to HIV treatment and prevention, is needed for widespread scale-up of this approach. METHODS: Within the Partners Demonstration Project, a prospective interventional project among 1013 serodiscordant couples in Kenya and Uganda, we offered ART to eligible HIV-positive partners and PrEP to HIV-negative partners before ART initiation and through the HIV-positive partner's first 6 months of ART use...
January 1, 2017: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/27927183/art-access-related-barriers-faced-by-hiv-positive-persons-linked-to-care-in-southern-ghana-a-mixed-method-study
#13
Augustine Ankomah, John Kuumuori Ganle, Margaret Yaa Lartey, Awewura Kwara, Priscilla Awo Nortey, Michael Perry Kweku Okyerefo, Amos Kankponang Laar
BACKGROUND: Timely and enduring access to antiretroviral therapy (ART) by HIV-infected individuals has been shown to substantially reduce HIV transmission risk, HIV-related morbidity and mortality. However, there is evidence that in addition to limited supply of antiretrovirals (ARVs) and linkage to ART in many low-income countries, HIV+ persons often encounter barriers in accessing ART-related services even in contexts where these services are freely available. In Ghana, limited research evidence exists regarding the barriers HIV+ persons already linked to ART face...
December 7, 2016: BMC Infectious Diseases
https://www.readbyqxmd.com/read/27923009/counseling-framework-for-hiv-serodiscordant-couples-on-the-integrated-use-of-antiretroviral-therapy-and-pre-exposure-prophylaxis-for-hiv-prevention
#14
Jennifer F Morton, Connie Celum, John Njoroge, Agnes Nakyanzi, Imeldah Wakhungu, Edna Tindimwebwa, Snaidah Ongachi, Eric Sedah, Emmanuel Okwero, Kenneth Ngure, Josephine Odoyo, Nulu Bulya, Jessica E Haberer, Jared M Baeten, Renee Heffron
BACKGROUND: For HIV-serodiscordant couples, integrated delivery of antiretroviral therapy (ART) for HIV-positive partners and time-limited pre-exposure prophylaxis (PrEP) for negative partners virtually eliminates HIV transmission. Standardized messaging, sensitive to the barriers and motivators to HIV treatment and prevention, is needed for widespread scale-up of this approach. METHODS: Within the Partners Demonstration Project, a prospective interventional project among 1013 serodiscordant couples in Kenya and Uganda, we offered ART to eligible HIV-positive partners and PrEP to HIV-negative partners before ART initiation and through the HIV-positive partner's first 6 months of ART use...
January 1, 2017: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/27919841/prevalence-of-non-adherence-to-highly-active-antiretroviral-therapy-and-its-related-clinical-and-therapeutic-factors-in-ouagadougou-burkina-faso
#15
O Guira, D S R Kaboré, G Dao, N Zagré, T M Zohoncon, V Pietra, J Simporé
: Introduction : Non-adherence to highly active antiretroviral therapy is deleterious in HIV/AIDS programs. This study contributes to the identification of its frequency and of the clinical and therapeutic factors that determine it. Material and methods : This cross-sectional study took place from December 15, 2013, to February 18, 2014, at the Saint Camille health care center and the Pietro Annigoni biomolecular research center in Ouagadougou. It includes adults who had been receiving antiretroviral therapy for at least three months and agreed to participate...
December 5, 2016: Médecine et Santé Tropicales
https://www.readbyqxmd.com/read/27917261/anti-hepatitis-c-virus-drugs-and-kidney
#16
REVIEW
Paul Carrier, Marie Essig, Marilyne Debette-Gratien, Denis Sautereau, Annick Rousseau, Pierre Marquet, Jérémie Jacques, Véronique Loustaud-Ratti
Hepatitis C virus (HCV) mainly targets the liver but can also induce extrahepatic manifestations. The kidney may be impacted via an immune mediated mechanism or a cytopathic effect. HCV patients are clearly at a greater risk of chronic kidney disease (CKD) than uninfected patients are, and the presence of CKD increases mortality. Interferon-based therapies and ribavirin are difficult to manage and are poorly effective in end-stage renal disease and hemodialysis. These patients should be given priority treatment with new direct anti-viral agents (DAAs) while avoiding peginterferon and ribavirin...
November 18, 2016: World Journal of Hepatology
https://www.readbyqxmd.com/read/27910750/antiretroviral-agents-looking-for-the-best-possible-chemotherapeutic-options-to-conquer-hiv
#17
Tahir Farooq, Arruje Hameed, Kanwal Rehman, Muhammad Ibrahim, Muhammad Imran Qadir, Muhammad Sajid Hamid Akash
For the last thirty years, ongoing efforts have revolutionized the antiretroviral therapy, which changed human immunodeficiency virus (HIV) infections from terrifying lethal diseases to chronic conditions. However, many challenges, like emergence of drug resistance, limited the scope of activity of currently existing anti-HIV agents. Quite often severe side effects and lifelong dependency are the major concerns of present era. All these issues have compelled the scientists to reconsider and refine the current therapies and also contemplate the pivotal priorities for the developments of novel therapeutic paradigms...
2016: Critical Reviews in Eukaryotic Gene Expression
https://www.readbyqxmd.com/read/27906024/rate-of-initial-highly-active-anti-retroviral-therapy-regimen-change-and-its-predictors-among-adult-hiv-patients-at-university-of-gondar-referral-hospital-northwest-ethiopia-a-retrospective-follow-up-study
#18
Degefaye Zelalem Anlay, Zinahbizu Abay Alemayehu, Berihun Assefa Dachew
BACKGROUND: Regimen change is a major challenge for the sustainability of human immunodeficiency virus (HIV) treatment program. In a resource limited setting where treatment options are limited, designing strategies to increase the durability of original regimen are essential. However, information's on rate of initial regimen change and its predictors is scarce in Ethiopia. Therefore, the purpose of this study was to assess the rate of initial highly active anti retroviral therapy (HAART) regimen change and its predictors among adult HIV patients at the University of Gondar Referral Hospital, Northwest Ethiopia...
February 17, 2016: AIDS Research and Therapy
https://www.readbyqxmd.com/read/27906007/what-happens-to-cardiovascular-system-behind-the-undetectable-level-of-hiv-viremia
#19
REVIEW
Gabriella d'Ettorre, Giancarlo Ceccarelli, Paolo Pavone, Pietro Vittozzi, Gabriella De Girolamo, Ivan Schietroma, Sara Serafino, Noemi Giustini, Vincenzo Vullo
Despite the combined antiretroviral therapy has improved the length and quality of life of HIV infected patients, the survival of these patients is always decreased compared with the general population. This is the consequence of non-infectious illnesses including cardio vascular diseases. In fact large studies have indicated an increased risk of coronary atherosclerotic disease, myocardial infarction even in HIV patients on cART. In HIV infected patients several factors may contribute to the pathogenesis of cardiovascular problems: life-style, metabolic parameters, genetic predisposition, viral factors, immune activation, chronic inflammation and side effects of antiretroviral therapy...
April 27, 2016: AIDS Research and Therapy
https://www.readbyqxmd.com/read/27905840/combining-cell-and-gene-therapy-in-an-effort-to-eradicate-hiv
#20
Thor A Wagner
More than 30 million people are infected with HIV, and HIV remains the fifth leading cause of disability-adjusted life years worldwide. Antiretroviral therapy (ART) dramatically decreases mortality rate, but there are side effects, long-term toxicities, expenses, stigmas, and inconveniences associated with chronic treatment, and HIV-infected individuals on ART have an increased risk of malignancies, cardiovascular disease, neurologic disease, and shortened life expectancy. Therefore, a cure for HIV remains an important goal...
December 2016: AIDS Patient Care and STDs
keyword
keyword
80810
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"